Skip to main content
Clinical Trials/NCT03455153
NCT03455153
Completed
Not Applicable

The Association of Physical Activity Levels and Inflammatory Markers in COPD Patients Following Pulmonary Rehabilitation

University of Lincoln3 sites in 1 country18 target enrollmentMay 2, 2018
ConditionsCOPD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
COPD
Sponsor
University of Lincoln
Enrollment
18
Locations
3
Primary Endpoint
Cytokines
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

COPD is characterised by irreversible airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response. This inflammation can be amplified with flare-ups that are commonly seen in COPD patients. Pulmonary rehabilitation is one of the most effective methods of managing chronic obstructive pulmonary disease (COPD). Pulmonary rehabilitation has been seen to induce improvements in functional capacity and quality.

In healthy individuals, exercise has been shown to induce an anti-inflammatory response when performed regularly. However, the effects of exercise on inflammation in COPD are unclear. Our initial CIMPRES-COPD study has looked into the effects of short-term exercise, as part of pulmonary rehabilitation, on inflammation. However, this trial will examine the inflammatory response in COPD patients who are most active following pulmonary rehabilitation against those who are least active.

This study will split participants into 2 groups according to physical activity level following pulmonary rehabilitation. We will recruit 40 COPD patients who provided a sample in the initial CIMPRES-COPD study to explore inflammatory responses in those who are most active and least active. By better understanding the mechanisms of how long-term physical activity levels affects inflammation in COPD, we could design better interventions to increase physical activity levels following pulmonary rehabilitation.

Registry
clinicaltrials.gov
Start Date
May 2, 2018
End Date
October 2, 2018
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients diagnosed with any severity of COPD (according to British Thoracic Society criteria, i.e. \>10 pack year smoking history and post bronchodilator spirometry FEV1/FVC ratio \<0.70 and FEV\<80%)
  • Previously enrolled on pulmonary rehabilitation providing at least one sample for the CIMPRES-COPD trial.

Exclusion Criteria

  • Any unstable ongoing cardiovascular events.
  • Other active inflammatory conditions (e.g. rheumatoid arthritis, cancer).
  • Known asthma, allergic rhinitis or other respiratory disease (bronchiectasis, pulmonary fibrosis).

Outcomes

Primary Outcomes

Cytokines

Time Frame: May 2018 - August 2018

Changes in concentration of inflammatory cytokines in the plasma of all participants using ELISA's (mg/L)

Secondary Outcomes

  • Leukocyte count(May 2018 - August 2018)
  • Cell function(May 2018 - August 2018)
  • Cell sensitivity to corticosteroids(May 2018 - August 2018)

Study Sites (3)

Loading locations...

Similar Trials